Summary of Study ST002527

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001627. The data can be accessed directly via it's Project DOI: 10.21228/M8D434 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST002527
Study Title	HPLC-MS-MS analysis amino acid levels in PDAC IF samples upon arginase inhibition
Study Summary	To test the hypothesis that myeloid arginase-1 activity could be responsible for pancreatic ductal adenocarninoma microenvironmental arginine starvation (PMID: 30990168), we generated orthotopic allograft mPDAC tumors in a mouse model with myeloid specific Arg1 knockout (LysM-Cre+/+-; Arg1fl/fl) and control animals (Arg1fl/fl). We also tested this with pharmacological inhibition of arginase-1 with the small-molecule inhibitor CB-1158. We then isolated IF from these tumors at end-stage and measured the levels of amino acids including arginine and ornithine in these samples.
Institute	University of Chicago
Last Name	Apiz Saab
First Name	Juan
Address	929 E. 57th St.
Email	japizsaab@uchicago.edu
Phone	7738346506
Submit Date	2022-08-05
Raw Data Available	Yes
Raw Data File Type(s)	raw(Thermo)
Analysis Type Detail	LC-MS
Release Date	2023-04-13
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002639
Treatment Summary:	For genetically modified mice, LysM-Cre and Arg1fl/fl C57BL6J mice were bred to generate LysM-Cre +/+; Arg1fl/fl and litter mate control Arg1fl/fl mice. Orthotopic pancreatic cancer tumors were implanted in C57BL6J mice at 8-12 weeks of age. At endpoint, mice were euthanized by cervical dislocation, and tumors were harvested for TIF extraction. For Pharmacological inhibition, orthotopic tumors were implanted in C57BL6J mice at 8-12 weeks of age. 4 weeks after induction, once tumors were close end stage disease, CB-1158 (MedChem Express) dissolved in sterile water was administered by oral gavage at 100mg/kg. The acidity caused by the HCl in the drug solution was neutralized by adding equivalent amount of NaOH and an equivalent NaCl in sterile water solution was prepared as vehicle. 2hrs after treatment with CB-1158 or vehicle, mice were euthanized by cervical dislocation, and tumors were harvested for TIF extraction.

Treatment ID:

TR002639

Treatment Summary:

For genetically modified mice, LysM-Cre and Arg1fl/fl C57BL6J mice were bred to generate LysM-Cre +/+; Arg1fl/fl and litter mate control Arg1fl/fl mice. Orthotopic pancreatic cancer tumors were implanted in C57BL6J mice at 8-12 weeks of age. At endpoint, mice were euthanized by cervical dislocation, and tumors were harvested for TIF extraction. For Pharmacological inhibition, orthotopic tumors were implanted in C57BL6J mice at 8-12 weeks of age. 4 weeks after induction, once tumors were close end stage disease, CB-1158 (MedChem Express) dissolved in sterile water was administered by oral gavage at 100mg/kg. The acidity caused by the HCl in the drug solution was neutralized by adding equivalent amount of NaOH and an equivalent NaCl in sterile water solution was prepared as vehicle. 2hrs after treatment with CB-1158 or vehicle, mice were euthanized by cervical dislocation, and tumors were harvested for TIF extraction.